Bayer discontinues anticoagulant study
Bayer has discontinued a study with an important drug hopeful due to lack of efficacy. A Phase III study investigating the drug Asundexian in patients with atrial fibrillation and stroke risk was terminated prematurely, the company announced late on Sunday evening. The anticoagulant was being traded as the successor to the drug Xarelto and, according to earlier information, was expected to generate peak annual revenues of more than five billion euros in the long term.
Asundexian was found to be less effective than the standard treatment, the company said. Bayer will continue to analyze the data. Asundexian contains an active ingredient that researchers hope will reduce the risk of bleeding compared to current drugs.
The discontinuation of the study on Asundexian is a setback for Bayer's Pharmaceuticals division, as this drug was touted to have significant revenue potential in the field of Medicine. Despite the lack of efficacy, Bayer's Chemistry team will persist in analyzing the data to gain insights for future Research.
Source: www.dpa.com
